secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001171843-23-006911
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Q3 net loss $10.0M ($0.08/shr); cash $164M; CEO succession to Bisker-Leib
--------------------------------------------------------------------------------

- Net loss for Q3 2023 was $10.0M ($0.08/shr) vs $12.0M ($0.12/shr) in Q3 2022; 9-month net loss $29.1M.
- Cash and marketable securities $164M as of Sep 30, 2023, providing cash runway into 2026.
- CEO succession: President/COO Vered Bisker-Leib to become CEO; current CEO Thomas Schuetz to President of R&D and Vice Chair, effective Jan 9, 2024.
- CTX-009 Ph2/3 COMPANION-002 (BTC) top line data expected H2 2024; initial data from COMPANION-003 (CRC) expected by year-end 2023.
- CTX-8371 IND cleared; Phase 1 trial to start Q4 2023. CTX-471 dose-escalation completed; expansion expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/0001171843-23-006911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323006911/f8k_110823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer